Sanofi India Limited has accepted the cessation of Nakul Verma as a member of its Senior Management Personnel (SMP), effective from the close of business hours on July 31, 2026. The change stems from Verma’s transition to another role within the broader Sanofi group, indicating an internal lateral move rather than a departure from the company ecosystem. This update ensures regulatory transparency regarding leadership changes at the listed entity.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) on July 31, 2026. Haresh Vala, Company Secretary and Compliance Officer of Sanofi India Limited, signed the communication, confirming adherence to statutory reporting requirements.

Regulatory Framework

The notification aligns with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. These regulations mandate timely disclosure of any changes in senior management personnel to ensure market participants are informed of shifts in key decision-making roles.

Leadership Transition Details

Nakul Verma held the position of Public Affairs and Market Access-Head within the company’s senior management structure. His exit from this specific SMP designation does not imply a termination of employment with the Sanofi group but reflects a reassignment to a different capacity within the organization. Such internal transitions are common in large multinational corporations and typically aim to optimize resource allocation across different business units or geographic regions.

What the Numbers Show

While this filing involves personnel changes rather than financial metrics, the timing of the transition—effective July 31, 2026—coincides with the end of the fiscal year for many Indian entities. This suggests that the handover of responsibilities related to public affairs and market access will be completed before the commencement of the new fiscal cycle, ensuring continuity in stakeholder communications and market strategy execution during the critical period of annual reporting and strategic planning.

Sanofi reported second-quarter adjusted earnings per share (EPS) of $1.21, beating the analyst consensus estimate of $1.09 by 11.01 percent. The pharmaceutical company posted quarterly sales of $13.482 billion (€11.597 billion), surpassing the $12.65 billion estimate. While the financial results reflect strong operational momentum, CEO Belén Garijo signaled a shift in strategy, stating that recent pipeline setbacks reflected weaknesses in decision-making rather than scientific capability.

Garijo announced a more disciplined approach to research and development, raising the bar for advancing programs into late-stage trials. The company is conducting an ongoing portfolio review to focus resources on medicines with the strongest scientific merit and commercial potential. This strategic pivot follows the discontinuation of several pipeline assets, including amlitelimab, itepekimab, and balinatunfib. Management emphasized greater scientific rigor and clearer accountability moving forward.

Key Financial Metrics

Segment Performance and Drivers

Sales growth was primarily fueled by the blockbuster drug Dupixent, which saw sales increase by 37.6% to €5.154 billion, crossing the €5 billion quarterly threshold for the first time. Global sales were driven by strong volume growth across approved indications, with Dupixent retaining a leading market position. Recent pharma launches, including Ayvakit, ALTUVIIIO, and Sarclisa, contributed significantly, with their combined sales rising 48.3% to €1.3 billion.

Conversely, vaccines sales declined 4.7% to €1.15 billion, weighed down by lower sales of influenza, meningitis, travel, and endemic vaccines. However, Beyfortus sales rose 54.2% to €108 million, benefiting from expanded geographical availability and use in the Southern Hemisphere. Despite the strong top-line performance, reported IFRS net income fell 91.3% to €343 million due to significant one-off items, while business operating income increased 35.8% at constant exchange rates (CER) to €3,291 million.

What the Numbers Show

The divergence between IFRS net income and business net income underscores the impact of non-recurring items on reported profitability. While IFRS net income plummeted 91.3%, business net income grew 31.0% at CER, indicating that core operational health remains strong. The surge in free cash flow (+86.8% to €2,670 million) alongside rising R&D spend suggests that the company is maintaining liquidity while investing heavily in future growth drivers like Dupixent, which is now projected to reach around €25 billion in sales by 2030.

Guidance and Outlook

Sanofi upgraded its full-year 2026 guidance, projecting sales growth of approximately 10% at CER, up from prior high single-digit expectations. Fiscal 2026 sales are forecast at $55.789 billion compared to the consensus of $55.85 billion. Management expects growth to moderate in the second half due to tougher year-over-year comparisons, including last year’s new Dupixent indication launches and the July 2025 consolidation of AYVAKIT. The company also anticipates fewer one-time gross margin benefits and a smaller boost from share repurchases.